CoChat

Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study

Open access

Published version of a preprint

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

Purpose: To investigate circulating tumor DNA (ctDNA) RAS mutant (MT) incidence before salvage-line treatment and the clinicopathological features and molecular biological factors associated with the efficacy of anti-epithelial growth factor receptor (EGFR) monoclonal antibody (mAb) rechallenge for tissue RAS / BRAF wild type (WT) metastatic colorectal cancer (mCRC). Methods: This multi-institutional retrospective observational study included 74 patients with mCRC with tissue RAS/BRAF WT refractory to first-line chemotherapy containing anti-EGFR mAb. ctDNA RAS status was assessed using the OncoBEAM™ RAS CRC Kit. We explored the clinicopathological features associated with ctDNA RAS status and the factors related to anti-EGFR mAb rechallenge efficacy in multivariate Cox proportional hazard regression. Results: The incidence of RAS MT in ctDNA was 40.5% (30/74), which was associated with primary tumor resection ( P = 0.016), liver metastasis ( P < 0.001), and high tumor marker levels ( P < 0.001). Among the 39 patients treated with anti-EGFR mAb rechallenge, those with ctDNA RAS WT showed significantly longer progression-free survival (PFS) than those with ctDNA RAS MT (median 4.1 vs. 2.7 months, hazard ratio [HR] = 0.39, P = 0.045). Patients who responded to first-line anti-EGFR mAb showed significantly longer PFS (HR = 0.21, P = 0.0026) and overall survival (OS) (HR = 0.23, P = 0.026) than those with stable disease. Conclusions: The incidence of ctDNA RAS MT mCRC was 40.5%, which was associated with liver metastases and high tumor volumes. Anti-EGFR mAb rechallenge may be effective for patients with mCRC who responded to first-line chemotherapy containing anti-EGFR mAb. No patients with RAS MT in ctDNA responded to anti-EGFR mAb rechallenge.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00432-024-05893-1

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 STROBE flow diagram. WT, wild type; ctDNA, circulating tumor DNA; MT, mutant type; EGFR, epidermal growth factor receptor; mAb, monoclonal antibody; BSC, best supportive care
Fig. 1 STROBE flow diagram. WT, wild type; ctDNA, circulating tumor DNA; MT, mutant type; EGFR, epidermal growth factor receptor; mAb, monoclonal antibody; BSC, best supportive careCC BY · PubMed Central
Fig. 2 Progression-free survival (PFS) and overall survival (OS) after anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) rechallenge for patients with metastatic colorectal cancer (mCRC) with circulating tumor DNA (ctDNA) RAS wild-type (WT) or mutant (MT) (n = 39). MST, median survival time; CI, confidence interval; NA, not applicable
Fig. 2 Progression-free survival (PFS) and overall survival (OS) after anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) rechallenge for patients with metastatic colorectal cancer (mCRC) with circulating tumor DNA (ctDNA) RAS wild-type (WT) or mutant (MT) (n = 39). MST, median survival time; CI, confidence interval; NA, not applicableCC BY · PubMed Central
Fig. 3 Progression-free survival (PFS) and overall survival (OS) after anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) for metastatic colorectal cancer (mCRC) patients showing partial response (PR) or stable disease (SD) in first-line anti-EGFR mAb (n = 33). *PR/SD in first line: patients with mCRC who had PR or SD during first-line anti-EGFR mAb. MST, median survival time; CI, confidence interval; NA, not applicable
Fig. 3 Progression-free survival (PFS) and overall survival (OS) after anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) for metastatic colorectal cancer (mCRC) patients showing partial response (PR) or stable disease (SD) in first-line anti-EGFR mAb (n = 33). *PR/SD in first line: patients with mCRC who had PR or SD during first-line anti-EGFR mAb. MST, median survival time; CI, confidence interval; NA, not applicableCC BY · PubMed Central
Fig. 4 Progression-free survival (PFS) and overall survival (OS) for anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) rechallenge for patients with metastatic colorectal cancer (mCRC) (anti-EGFR mAb-free interval ≥ 12 months or < 12 months) (n = 37) MST, median survival time; CI, confidence interval; NA, not applicable
Fig. 4 Progression-free survival (PFS) and overall survival (OS) for anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) rechallenge for patients with metastatic colorectal cancer (mCRC) (anti-EGFR mAb-free interval ≥ 12 months or < 12 months) (n = 37) MST, median survival time; CI, confidence interval; NA, not applicableCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 8

Metadata

Authors
Fukuda, K., Osumi, H., Yoshinami, Y., Ooki, A., Takashima, A., Wakatsuki, T., Hirano, H., Nakayama, I., Ouchi, K., Sawada, R., Fukuoka, S., Ogura, M., Takahari, D., Chin, K., Shoji, H., Okita, N., Kato, K., Ishizuka, N., Boku, N., Yamaguchi, K., & Shinozaki, E.
Affiliations
  • The Cancer Institute Hospital (JP)
  • National Cancer Center Hospital (JP)
  • Tohoku University Hospital (JP)
  • Jikei University School of Medicine (JP)
  • Kyoto University (JP)
  • IMSUT Hospital (JP)
Corresponding author
Shinozaki, Eiji
Venue
Journal of Cancer Research and Clinical Oncology
Published
2024-07-27
Volume
150
Issue
7
Pages
369-369
ISSN
  • 0084-5353 (ISSN-L)
  • 1432-1335
OpenAlex
W4401052054
Cited by
5
References
39
Citations by year
2026: 3 · 2025: 2
FWCI
0.85
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Cancer Research and Clinical Oncology (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords
metastatic colorectal cancer, anti-EGFR monoclonal antibody, circulating tumor DNA, RAS mutations, BRAF wild-type, progression-free survival, liver metastasis, first-line chemotherapy response, predictive biomarkers
MeSH terms
Circulating Tumor DNA, Antineoplastic Agents, Immunological, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Mutation, Retrospective Studies, Colorectal Neoplasms, Proto-Oncogene Proteins B-raf, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study. https://app.cochat.ai/papers/10.1007/s00432-024-05893-1
The paper
Fukuda, K., Osumi, H., Yoshinami, Y., Ooki, A., Takashima, A., Wakatsuki, T., Hirano, H., Nakayama, I., Ouchi, K., Sawada, R., Fukuoka, S., Ogura, M., Takahari, D., Chin, K., Shoji, H., Okita, N., Kato, K., Ishizuka, N., Boku, N., . . . Shinozaki, E. (2024). Efficacy of anti-epidermal growth factor antibody rechallenge in RAS/BRAF wild-type metastatic colorectal cancer: a multi-institutional observational study. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05893-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.